Member Directory
Immunotherapeutics company targeting a new class of tumour specific antigens
Essen BioScience is a world leader in the field of innovative cell-based assays, reagents, instrumentation and custom services for discovery research. Our specialities include phenotypic 'live content' kinetic imaging assays based around IncuCyte Zoom (e.g. angiogenesis, neurite outgrowth, cell migration/invasion, apoptosis etc.) and high throughput automated electrophysiology for ion channel drug discovery and safety (e.g. hERG assays). Our live content imaging solution has been adopted by laboratories across all 10 of the world’s top pharmaceutical companies as well as more than 150 leading biotechnology and academic research institutions.
Eurofins PSS® is part of Eurofins Scientific, an international life sciences company, providing a unique range of analytical testing services across multiple industries, through a network of over 900 laboratories in 62 countries, and c.a. 62,000 employees.
At Eurofins PSS Insourcing Solutions we hire Dedicated, full-time, and qualified Eurofins scientific staff working at client’s site using client’s facilities, equipment, computer systems, SOPs and methods
Our bespoke on-site management report to senior management at Eurofins PSS UK, ensuring service delivery and support, Comprehensive technical and client service training and leadership development to maximise talent with access to Eurofins in-house technical staff and resources
Selcia Ltd headquartered in Ongar, Essex, UK, is a leading worldwide provider of contract research services. Selcia Discovery provides integrated small molecule drug discovery, including general medicinal chemistry and biology capabilities, applicable across all target classes with a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products; (2) capillary electrophoresis-based fragment and natural product screening; and (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Selcia Radiolabelling specialises in GMP radiolabelled API and in 14C custom radiolabelling for metabolism, distribution and environmental fate studies.
A new synthetic biology start up
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of- the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.
ExecMind is an international Executive Search boutique company focused on recruitment of senior scientists (PhD level) and senior and top management in Life Science industry. We cover all European countries, including Baltic countries and Scandinavia, West and Central Eastern Europe, South Europe. Outside Europe, we run searches in North America (US and Canada) and Asia. We decided to be highly specialized company and thanks to our understanding of the industry we effectively help our Clients to expand their teams and business.. Our area of expertise in Life Science and new technology industry:. •
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies, where the second binding site is in the constant Fc region of an antibody, offering unprecedented ease in the discovery, development and manufacturing of bispecific antibody products. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including, AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.. . For more information visit www.f-star.com